Improving diagnostic methods for low HER2 breast cancer and targeted therapy
Official title: Next-generation diagnostic approaches for HER2-low breast cancer and trastuzumab deruxtecan therapy
Funded at Yale University · NIH-11063782 · Data updated 2026-11-12
This study is working on a new test to help doctors better identify breast cancer patients with low HER2 levels, so they can choose the best treatment options, especially for those who might benefit from a specific therapy called trastuzumab deruxtecan.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $34,522 |
| NIH project number | 5F30CA287869-02 |
| Project ID | NIH-11063782 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with HER2-low or HER2-negative breast cancer who may benefit from targeted therapies.
✕Less likely to help
Patients with HER2-positive breast cancer or those who do not have breast cancer may not receive any benefit from this research.
What this research studies
This research focuses on developing advanced diagnostic techniques to better identify patients with low HER2 expression in breast cancer, which is crucial for determining the most effective treatment options. The study aims to create a high-sensitivity HER2 assay that can accurately classify patients, addressing the limitations of outdated methods that often lead to misdiagnosis. By analyzing the spatial patterns of HER2 expression and tumor characteristics, the research seeks to enhance the precision of treatment selection, particularly for those eligible for trastuzumab deruxtecan therapy.
Why it matters
Potential benefit: If successful, this research could lead to more accurate diagnoses and improved treatment outcomes for patients with HER2-low breast cancer.
How similar studies have gone: Previous research has shown promise in developing advanced diagnostic techniques for breast cancer, indicating potential success for this novel approach.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Robbins, Charles John — Yale University
- Study coordinator: Robbins, Charles John
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.